Cargando…
A monoclonal antibody specifically reactive with Ewing's sarcoma.
We have developed a mouse monoclonal antibody 5C11 (IgG2a) against cell surface antigen of Ewing's sarcoma (ES). 5C11 specifically reacted with ESs but not with other small round cell tumours in childhood, i.e. neuroblastomas, primitive neuroectodermal tumours (PNETs), rhabdomyosarcomas and mal...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247257/ https://www.ncbi.nlm.nih.gov/pubmed/2605097 |
_version_ | 1782150943147556864 |
---|---|
author | Hara, S. Ishii, E. Tanaka, S. Yokoyama, J. Katsumata, K. Fujimoto, J. Hata, J. |
author_facet | Hara, S. Ishii, E. Tanaka, S. Yokoyama, J. Katsumata, K. Fujimoto, J. Hata, J. |
author_sort | Hara, S. |
collection | PubMed |
description | We have developed a mouse monoclonal antibody 5C11 (IgG2a) against cell surface antigen of Ewing's sarcoma (ES). 5C11 specifically reacted with ESs but not with other small round cell tumours in childhood, i.e. neuroblastomas, primitive neuroectodermal tumours (PNETs), rhabdomyosarcomas and malignant lymphomas. 5C11 did not react with any other tumours in children except for hepatoblastomas. No reactivity has been identified in normal tissues with the exception of fetal hepatocytes. Immunoelectron microscopically, 5C11 reactive antigen was located on cell membrane of ES cells. Biochemically, 5C11 immunoprecipitated a cell surface protein having molecular weight of 81,000 Da. 5C11 is the first antibody which can clearly distinguish ES from neurogenic tumours, especially from PNETs which were recently reported to have common features to ESs regarding chromosal abnormality and proto-oncogene expression but show evident differentiation into neurogenic direction. The results strongly indicate the usefulness of 5C11 not only for diagnostic purpose when no specific marker is available but also for studying the histogenesis of ES. In addition, no reactivity in normal tissue implies its potential application as a therapeutic reagent when the management of ES patients is still a great problem in clinical field. IMAGES: |
format | Text |
id | pubmed-2247257 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1989 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22472572009-09-10 A monoclonal antibody specifically reactive with Ewing's sarcoma. Hara, S. Ishii, E. Tanaka, S. Yokoyama, J. Katsumata, K. Fujimoto, J. Hata, J. Br J Cancer Research Article We have developed a mouse monoclonal antibody 5C11 (IgG2a) against cell surface antigen of Ewing's sarcoma (ES). 5C11 specifically reacted with ESs but not with other small round cell tumours in childhood, i.e. neuroblastomas, primitive neuroectodermal tumours (PNETs), rhabdomyosarcomas and malignant lymphomas. 5C11 did not react with any other tumours in children except for hepatoblastomas. No reactivity has been identified in normal tissues with the exception of fetal hepatocytes. Immunoelectron microscopically, 5C11 reactive antigen was located on cell membrane of ES cells. Biochemically, 5C11 immunoprecipitated a cell surface protein having molecular weight of 81,000 Da. 5C11 is the first antibody which can clearly distinguish ES from neurogenic tumours, especially from PNETs which were recently reported to have common features to ESs regarding chromosal abnormality and proto-oncogene expression but show evident differentiation into neurogenic direction. The results strongly indicate the usefulness of 5C11 not only for diagnostic purpose when no specific marker is available but also for studying the histogenesis of ES. In addition, no reactivity in normal tissue implies its potential application as a therapeutic reagent when the management of ES patients is still a great problem in clinical field. IMAGES: Nature Publishing Group 1989-12 /pmc/articles/PMC2247257/ /pubmed/2605097 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Hara, S. Ishii, E. Tanaka, S. Yokoyama, J. Katsumata, K. Fujimoto, J. Hata, J. A monoclonal antibody specifically reactive with Ewing's sarcoma. |
title | A monoclonal antibody specifically reactive with Ewing's sarcoma. |
title_full | A monoclonal antibody specifically reactive with Ewing's sarcoma. |
title_fullStr | A monoclonal antibody specifically reactive with Ewing's sarcoma. |
title_full_unstemmed | A monoclonal antibody specifically reactive with Ewing's sarcoma. |
title_short | A monoclonal antibody specifically reactive with Ewing's sarcoma. |
title_sort | monoclonal antibody specifically reactive with ewing's sarcoma. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247257/ https://www.ncbi.nlm.nih.gov/pubmed/2605097 |
work_keys_str_mv | AT haras amonoclonalantibodyspecificallyreactivewithewingssarcoma AT ishiie amonoclonalantibodyspecificallyreactivewithewingssarcoma AT tanakas amonoclonalantibodyspecificallyreactivewithewingssarcoma AT yokoyamaj amonoclonalantibodyspecificallyreactivewithewingssarcoma AT katsumatak amonoclonalantibodyspecificallyreactivewithewingssarcoma AT fujimotoj amonoclonalantibodyspecificallyreactivewithewingssarcoma AT hataj amonoclonalantibodyspecificallyreactivewithewingssarcoma AT haras monoclonalantibodyspecificallyreactivewithewingssarcoma AT ishiie monoclonalantibodyspecificallyreactivewithewingssarcoma AT tanakas monoclonalantibodyspecificallyreactivewithewingssarcoma AT yokoyamaj monoclonalantibodyspecificallyreactivewithewingssarcoma AT katsumatak monoclonalantibodyspecificallyreactivewithewingssarcoma AT fujimotoj monoclonalantibodyspecificallyreactivewithewingssarcoma AT hataj monoclonalantibodyspecificallyreactivewithewingssarcoma |